{"drugs":["Avage","Fabior","Tazarotene","Tazorac"],"mono":{"0":{"id":"924281-s-0","title":"Generic Names","mono":"Tazarotene"},"1":{"id":"924281-s-1","title":"Dosing and Indications","sub":{"0":{"id":"924281-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acne vulgaris:<\/b> (cream; Tazorac(R)), after cleansing the face, apply 0.1% cream TOPICALLY every evening<\/li><li><b>Acne vulgaris:<\/b> (gel; Tazorac(R)), after cleansing the face, apply 0.1% gel TOPICALLY every evening for mild to moderate severity facial acne<\/li><li><b>Acne vulgaris:<\/b> (foam; Fabior(TM)), after cleansing the face and\/or upper trunk, apply 0.1% foam TOPICALLY every evening<\/li><li><b>Fine wrinkles on face; Adjunct - Solar degeneration; Adjunct:<\/b> Avage(TM), apply pea-sized amount TOPICALLY to lightly cover the entire face (including eyelids if  desired) once daily at bedtime<\/li><li><b>Plaque psoriasis:<\/b> Tazorac (R); initial, apply 0.05% gel or cream TOPICALLY every night to affected area; may increase to 0.1% gel or cream TOPICALLY every night if indicated and tolerated<\/li><\/ul>"},"1":{"id":"924281-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in children less than 12 years of age for acne (Tazorac (R) cream and gel and Fabior(TM) foam), less than 18 years of age for psoriasis (Tazorac (R) cream), and less than 12 years of age for psoriasis ((Tazorac (R) gel)<\/li><li>Safety and efficacy not established in children less than 17 years of age<\/li><li><b>Acne vulgaris:<\/b> (cream; Tazorac(R)) 12 years and older, after cleansing the face, apply 0.1% cream TOPICALLY every evening<\/li><li><b>Acne vulgaris:<\/b> (gel; Tazorac(R)) 12 years and older, after cleansing the face, apply 0.1% gel TOPICALLY every evening for mild to moderate severity facial acne<\/li><li><b>Acne vulgaris:<\/b> (foam; Fabior(TM)) 12 years and older, after cleansing the face and\/or upper trunk, apply 0.1% foam TOPICALLY every evening<\/li><li><b>Plaque psoriasis:<\/b> Tazorac (R) gel (12 years and older); initial, apply 0.05% gel TOPICALLY every night to affected area; may increase to 0.1% gel or cream TOPICALLY every night if indicated and tolerated<\/li><\/ul>"},"3":{"id":"924281-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acne vulgaris<\/li><li>Fine wrinkles on face; Adjunct - Solar degeneration; Adjunct<\/li><li>Plaque psoriasis<\/li><\/ul>"}}},"3":{"id":"924281-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924281-s-3-9","title":"Contraindications","mono":"pregnancy <br\/>"},{"id":"924281-s-3-10","title":"Precautions","mono":"<ul><li>abraded or eczematous skin; may cause severe irritation; avoid use<\/li><li>concomitant dermatologic agents or cosmetics with drying effect; avoid use<\/li><li>contact with mouth, eyes, or mucous membranes; avoid contact<\/li><li>flammable; avoid exposure of foam to open fire or flame, or smoking<\/li><li>hypersensitivity or tolerability reactions, local; use caution<\/li><li>redness, peeling, burning, or excessive itching of the skin may occur; reduce frequency of application or temporarily discontinue use<\/li><li>skin cancer, personal or family history<\/li><li>sunburned skin; avoid use until skin is fully recovered<\/li><li>sunlight or UV light exposure; increased risk of sensitivity and\/or burning; avoid exposure<\/li><li>women of childbearing potential; avoid becoming pregnant with effective contraception use during treatment<\/li><li>to report suspected adverse reactions, contact the US Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924281-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"924281-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"924281-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Dry skin (cream, greater than 1% to 30%; gel, 1% to 30%; foam, 7%), Erythema (foam, 6%; cream, 10% to 30%; gel, 10% to 30%), Pain of skin (foam, 1%; cream, greater than 1% to less than 10%; gel, 1% to 30%), Pruritus (foam, 1%; cream, 1% to 23%; gel, 10% to 30%), Psoriasis, Worsening (cream, greater than 1% to less than 10%; gel, 10% to 30%), Skin irritation (cream, 1% to less than 10%; foam, 14%; gel, 1% to 30%), Stinging of skin (cream, 1% to less than 10%; gel, 10% to 30%)<br\/><b>Serious<\/b><br\/><b>Dermatologic:<\/b>Peeling of skin (foam, 6%; cream, greater than 1% to 30%; gel, 1% to 30%)<br\/>"},"6":{"id":"924281-s-6","title":"Drug Name Info","sub":{"0":{"id":"924281-s-6-17","title":"US Trade Names","mono":"<ul><li>Avage<\/li><li>Tazorac<\/li><li>Fabior<\/li><\/ul>"},"2":{"id":"924281-s-6-19","title":"Class","mono":"<ul><li>Dermatological Agent<\/li><li>Retinoid<\/li><\/ul>"},"3":{"id":"924281-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924281-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"924281-s-7","title":"Mechanism Of Action","mono":"<ul><li>Topical: Although tazarotene binds to all three members of the retinoic acid receptor family (alpha, beta, and gamma receptors), it binds selectively to beta and gamma receptors and probably modifies gene expression .<\/li><li>Antiacne agent-The mechanism of action of tazarotene in the treatment of acne vulgaris is not known, but studies suggest that it inhibits corneocyte accumulation in rhino mouse skin and cross-linked envelope formation in human keratocyte cultures .<\/li><li>Antipsoriatic-The mechanism of action of tazarotene in the treatment of psoriasis is not known. Skin studies done with tazarotene in animals and human cell cultures suggest that it has anti-inflammatory and antiproliferative actions in the skin through gene expression. Tazarotene, by directly reducing the keratinocyte&quot;s rate of proliferation, helps to normalize cell differentiation and inhibits the formation of a cornified envelope. Also, tazarotene may modify gene transcription or bind to transcription factors to reduce the erythema common in psoriasis .<\/li><\/ul>"},"8":{"id":"924281-s-8","title":"Pharmacokinetics","sub":[{"id":"924281-s-8-23","title":"Absorption","mono":"Topical: Minimal<br\/>"},{"id":"924281-s-8-24","title":"Distribution","mono":"Topical: 2 to 5%<br\/>"},{"id":"924281-s-8-25","title":"Metabolism","mono":"Topical: Hepatic: Active metabolite: Tazarotenic acid<br\/>"},{"id":"924281-s-8-26","title":"Excretion","mono":"Topical: Fecal and Renal  .<br\/>"},{"id":"924281-s-8-27","title":"Elimination Half Life","mono":"Topical: 18 h.<br\/>"}]},"9":{"id":"924281-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>topical use only; not for ophthalmic, oral, or intravaginal use<br\/><\/li><li><b>Topical<\/b><br\/><ul><li>avoid contact with eyes, eyelids, mouth, lips, and mucous membranes<\/li><li>use sunscreen and wear protective clothing during the day<\/li><li>(psoriasis) apply a thin film to dry lesions; use only enough to cover lesion and not surrounding skin<\/li><li>(psoriasis) apply any emollients 1 hour before application<\/li><li>(acne) apply thin film to clean, dry area where lesions appear<\/li><li>(acne, foam) gently massage into skin until foam disappears<\/li><li>(acne, foam) oxidizing agents such as benzoyl peroxide should be applied at a different time of day from tazarotene foam<\/li><li>(acne) wash hands after application of the gel, cream, and foam<\/li><li>(facial wrinkling)  makeup should be removed and the skin should be dry (eg,  after facial washing or a shower) prior to application; moisturizers or emollients may be applied  before or after tazarotene applications, ensuring that the first cream or lotion  applied has been absorbed and has dried completely<\/li><\/ul><\/li><\/ul>"},"10":{"id":"924281-s-10","title":"Monitoring","mono":"<ul><li>(acne) reduction in acne lesions is indicative of efficacy<\/li><li>(psoriasis) percent of body involvement and severity of lesions (scaling, erythema, lesion thickness) is indicative of efficacy<\/li><li>(foam) pregnancy test with a sensitivity of at least 25 milli-International Units\/mL; within 2 weeks prior to therapy initiation<\/li><li>(cream and gel) pregnancy test with a sensitivity of at least 50 milli-International Units\/mL; within 2 weeks prior to therapy initiation<\/li><li>signs or symptoms of skin toxicity (eg, severe burning, peeling, or redness)<\/li><\/ul>"},"11":{"id":"924281-s-11","title":"How Supplied","mono":"<ul><li><b>Avage<\/b><br\/>Topical Cream: 0.1 %<br\/><\/li><li><b>Fabior<\/b><br\/>Topical Foam: 0.1 %<br\/><\/li><li><b>Tazorac<\/b><br\/><ul><li>Topical Cream: 0.05 %, 0.1 %<\/li><li>Topical Gel\/Jelly: 0.05 %, 0.1 %<\/li><\/ul><\/li><\/ul>"},"12":{"id":"924281-s-12","title":"Toxicology","sub":[{"id":"924281-s-12-31","title":"Clinical Effects","mono":"<b>BEXAROTENE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose data is limited. ADVERSE EFFECTS: Hyperlipidemia and leukopenia are the dose-limiting toxicities following therapeutic administration of bexarotene.  Time to onset of leukopenia is generally 4 to 8 weeks after therapeutic use. Other common adverse effects that may occur include nausea, vomiting, diarrhea, pancreatitis, headaches, asthenia, hypothyroidism, elevated liver enzyme levels, and skin rashes. Liver failure was rarely reported following bexarotene therapy during clinical trials. <br\/>"},{"id":"924281-s-12-32","title":"Treatment","mono":"<b>BEXAROTENE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: ORAL: Activated charcoal; TOPICAL: Remove contaminated clothing and wash exposed area extremely thoroughly with soap and water.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Neutropenia: Filgrastim: 5 mcg\/kg\/day IV or subQ. Sargramostim: 250 mcg\/m(2)\/day IV over 4 hours.<\/li><li>Monitoring of patient: Monitor CBC with differential, hepatic enzymes, serum lipid levels, and thyroid function in symptomatic patients.<\/li><\/ul>"},{"id":"924281-s-12-33","title":"Range of Toxicity","mono":"<b>BEXAROTENE AND RELATED AGENTS<\/b><br\/>TOXICITY: A specific minimum toxic dose has not been established. Bexarotene doses up to 1000 mg\/m(2)\/day have been tolerated without acute toxic effects following short-term administration to patients with advanced cancer. THERAPEUTIC DOSE: ADULT: ORAL: 300 mg\/m(2)\/day as a single oral dose; after eight weeks, the total daily dosage may be escalated up to 400 mg\/m(2).<br\/>"}]},"13":{"id":"924281-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise female patients to use an effective form of birth control and avoid becoming pregnant during treatment, as drug may cause fetal harm.<\/li><li>Drug is flammable. Instruct patient to avoid smoking or exposure to fire or flames during and immediately following foam use.<\/li><li>Drug causes sensitivity to sun and weather extremes such as wind and cold. Advise patient to wear sunscreen daily, do not use tanning beds and sunlamps, and avoid weather extremes.<\/li><li>This drug may cause dryness, erythema, pruritus, burning, and peeling of skin.<\/li><li>Advise patient that symptomatic improvement may not be seen for at least a few weeks.<\/li><li>Tell patient to avoid drug contact with eyes\/eyelids, mouth, and eczematous or sunburned skin.<\/li><li>Instruct patient to apply drug to dry skin. Drug should be applied only to lesions and not to surrounding skin.<\/li><li>Patient should apply any emollients 1 hour before applying tazarotene.<\/li><li>Advise patient to avoid medications or cosmetics with a strong drying effect.<\/li><li>Advise patient to skip missed dose and continue with normal schedule.<\/li><\/ul>"}}}